Evidently PAG reckons the support for the scrip is not worth the trouble. Nor critical in mass to disrupt the Offer. If illiquid arbs are your bent, and payment late Aug, pay up to $1.90/share.
What is covered in the Full Insight:
Introduction to Fengxiang Offer
Details on Scrip Alternative
Offer Pricing and Market Implications
Regulatory and Shareholder Approval Process
Conclusion and Investor Considerations
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.